$39.480
+0.880 (+2.23%)Zum Schluss
THRM-News
THRM-Events
Board Approves New $400M Stock Repurchase Program
The Board of Directors authorized a new stock repurchase program of up to $400M of the company's issued and outstanding common stock. The new program will replace the company's existing stock repurchase program effective July 27, 2026, and will remain in effect for a three-year period. As of June 30, 2026, the prior program had approximately $110M of stock repurchase authorization remaining.
FY26 Revenue Consensus at $1.56B, Adjusted EBITDA View Raised to $185M-$200M
FY26 revenue consensus $1.56B. Raises FY26 adjusted EBITDA view to $185M-$200M from $175M-$195M; Adjusted free cash flow view to $85M-$100M from $80M-$100M.
Gentherm Reports Q2 Revenue of $416.2M
Reports Q2 revenue $416.2M, consensus $382.87M. "The Gentherm team demonstrated strong commercial performance with record quarterly revenue, while also scaling our core technologies into new markets. Our growth initiatives in both home and office, and medical markets continued to accelerate." said Bill Presley, the Company's President and CEO. "In addition, I was pleased with our execution during the quarter. The operating systems and key performance indicators we have put in place to drive more rigor and standardization throughout the business are yielding positive results."
Gentherm Receives FDA 510 Clearance for ThermAffyx System
Gentherm announced it received FDA 510 clearance for its patented ThermAffyx Patient Safety System. This Class II medical device combines active patient warming, securement and pressure reduction in a platform designed for robotic-assisted surgical procedures. Product trials at healthcare facilities are scheduled to begin in August, with revenue generation expected to commence in Q3.
Sees 2026 Adjusted EBITDA of $175M-$195M
Still sees 2026 adjusted EBITDA $175M-$195M.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.